Login to Your Account



Other News To Note


Thursday, December 1, 2011

• Curis Inc., of Lexington, Mass., inked an agreement with yhe Leukemia & Lymphoma Society (LLS) to support ongoing development of its oral small-molecule dual Pi3 kinase and HDAC inhibitor CUDC-907 for B-cell lymphoma and multiple myeloma. LLS will fund approximately half of the direct costs of the development of CUDC-907, up to $4 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription